PMID- 33986813 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2021 DP - 2021 TI - The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study. PG - 1347342 LID - 10.1155/2021/1347342 [doi] LID - 1347342 AB - OBJECTIVE: The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. METHODS: Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n = 48) and control group (CON; n = 44). Routine adjuvant chemotherapy (every 21 days, 4-8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (WBC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAEs). Other measures included treatment compliance, adverse events (AEs), and survival. RESULTS: WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7(th) course of chemotherapy (P=0.008), while grade 1 ANC reduction was dramatically lower than that in CON at the 7(th)course of chemotherapy (P=0.006). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON (P=0.051). MOX demonstrated a lower incidence of grade 3-4 myelosuppression (P < 0.05). AEs including grade 2-3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX (P < 0.05). No difference in survival was observed between the two groups (P > 0.05). CONCLUSION: Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer. CI - Copyright (c) 2021 Yajie Ji et al. FAU - Ji, Yajie AU - Ji Y AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. AD - Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. FAU - Li, Siyu AU - Li S AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Zhang, Xinyue AU - Zhang X AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Li, Qiong AU - Li Q AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Lu, Qing AU - Lu Q AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Chen, Weili AU - Chen W AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Liu, Yu AU - Liu Y AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Sheng, Jiayu AU - Sheng J AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Liang, Hongli AU - Liang H AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Jiang, Ke AU - Jiang K AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Li, Mengting AU - Li M AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Sha, Shanyan AU - Sha S AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. FAU - Wu, Huangan AU - Wu H AD - Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. AD - Key Laboratory of Acupuncture and Immunological Effects, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. FAU - Huang, Yan AU - Huang Y AD - Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. AD - Key Laboratory of Acupuncture and Immunological Effects, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. FAU - Xue, Xiaohong AU - Xue X AUID- ORCID: 0000-0001-5630-8731 AD - Department of Breast Surgery, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. LA - eng PT - Journal Article DEP - 20210425 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC8093063 COIS- The authors declare that they have no conflicts of interest. EDAT- 2021/05/15 06:00 MHDA- 2021/05/15 06:01 PMCR- 2021/04/25 CRDT- 2021/05/14 06:58 PHST- 2020/08/02 00:00 [received] PHST- 2021/04/05 00:00 [revised] PHST- 2021/04/15 00:00 [accepted] PHST- 2021/05/14 06:58 [entrez] PHST- 2021/05/15 06:00 [pubmed] PHST- 2021/05/15 06:01 [medline] PHST- 2021/04/25 00:00 [pmc-release] AID - 10.1155/2021/1347342 [doi] PST - epublish SO - Evid Based Complement Alternat Med. 2021 Apr 25;2021:1347342. doi: 10.1155/2021/1347342. eCollection 2021.